Dynavax’ Heplisav Phase III Data Bolsters Hep B Seroprotection Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-term data from study comparing Heplisav to GSK's Engerix-B shows 100 percent seroprotection 50 weeks post-vaccination.
You may also be interested in...
Merck And Dynavax Pair Up For Heplisav
Data from international Phase III study of the novel hepatitis B vaccine remain on track for first half 2008, Dynavax CEO Dina says.
Merck And Dynavax Pair Up For Heplisav
Data from international Phase III study of the novel hepatitis B vaccine remain on track for first half 2008, Dynavax CEO Dina says.
Dynavax Licenses Coley’s Toll-Like Receptor Adjuvant For Hep B Vaccine Candidate Heplisav
BLA asking approval of one-month, two-dose vaccine regimen anticipated in second half of 2008.